Curebase CEO, Tom Lemberg, Featured in Drug Discovery and Development's "9 Predictions for Pharma in 2022"
December 6, 2021
The pandemic has disrupted how biopharma meets the complex needs of patients in clinical research. “Thanks to these changes, patients who wish to participate in many clinical trials are no longer tied to single locations,” said Tom Lemberg, founder and CEO of Curebase, which has created a decentralized clinical trial software platform. “Patients have unique lifestyles, and study designs that cannot accommodate a patient’s needs fail to recruit participants effectively.”
Traditional clinical trials can often be burdensome for patients. “It’s not uncommon to see a trial requiring a patient to visit the same clinical trial site repeatedly, and those trials sometimes only secure a single patient for common conditions,” Lemberg said.
A growing number of studies now allow more flexibility in how patients choose to participate. “When participation can be handled virtually — at home, at local pharmacies, or with their own doctor — options are an effective way to engage patients successfully,” Lemberg said. “As we move into 2022, I expect we will see dynamic trial designs that give patients an ever-growing number of methods to participate in studies from home or amidst their busy lifestyle traveling the globe,” he added. “Biopharma must meet the needs of these people to accelerate studies and engage target patients.”
At Curebase, our mission is to bring quality medical innovations to patients faster and improve human wellbeing through more efficient clinical studies. We are proving that clinical research can be radically accelerated if we empower physicians everywhere to enroll patients in the communities where they live. By applying cutting edge clinical software and remote study management techniques to the problem, we are reinventing clinical trials and research from the ground up.
SOURCE Drug Discovery and Development